These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 6608979)

  • 1. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
    Langston JW; Ballard P
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):160-5. PubMed ID: 6608979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease: recent advances in therapy.
    Jankovic J
    South Med J; 1988 Aug; 81(8):1021-7. PubMed ID: 3043683
    [No Abstract]   [Full Text] [Related]  

  • 3. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
    Ballard PA; Tetrud JW; Langston JW
    Neurology; 1985 Jul; 35(7):949-56. PubMed ID: 3874373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
    Crossman AR; Clarke CE; Boyce S; Robertson RG; Sambrook MA
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):428-35. PubMed ID: 3119180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
    Doudet D; Gross C; Lebrun-Grandie P; Bioulac B
    Electromyogr Clin Neurophysiol; 1986 Dec; 26(8):711-27. PubMed ID: 3493894
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease.
    Lieberman AN
    Compr Ther; 1986 Mar; 12(3):25-9. PubMed ID: 3486090
    [No Abstract]   [Full Text] [Related]  

  • 9. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
    Ekesbo A; Andrén PE; Gunne LM; Tedroff J
    Neuroreport; 1997 Jul; 8(11):2567-70. PubMed ID: 9261828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Clarke CE; Sambrook MA; Mitchell IJ; Crossman AR
    J Neurol Sci; 1987 May; 78(3):273-80. PubMed ID: 3495642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease in 1984: an update.
    Lang AE; Blair RD
    Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
    Taylor JR; Elsworth JD; Roth RH; Sladek JR; Redmond DE
    Neuroscience; 1997 Dec; 81(3):745-55. PubMed ID: 9316026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
    Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
    Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D; Parkes JD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1975 Apr; 38(4):331-5. PubMed ID: 1095689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
    Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
    Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
    Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X
    Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Marsden CD; Jenner PG
    Ciba Found Symp; 1987; 126():239-56. PubMed ID: 3556086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.